Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
종목 코드 QTRX
회사 이름Quanterix Corp
상장일Dec 07, 2017
CEOToloue (Masoud)
직원 수471
유형Ordinary Share
회계 연도 종료Dec 07
주소900 Middlesex Turnpike
도시BILLERICA
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호01821
전화16173019400
웹사이트https://www.quanterix.com/
종목 코드 QTRX
상장일Dec 07, 2017
CEOToloue (Masoud)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음